Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.
about
Second-line chemotherapy for non-small cell lung cancer.Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.96-hour paclitaxel infusions: at least 93 hours too long.
P2860
Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Second-line chemotherapy with ...... r: report of a phase II trial.
@en
Second-line chemotherapy with ...... r: report of a phase II trial.
@nl
type
label
Second-line chemotherapy with ...... r: report of a phase II trial.
@en
Second-line chemotherapy with ...... r: report of a phase II trial.
@nl
prefLabel
Second-line chemotherapy with ...... r: report of a phase II trial.
@en
Second-line chemotherapy with ...... r: report of a phase II trial.
@nl
P2093
P2860
P921
P1433
P1476
Second-line chemotherapy with ...... r: report of a phase II trial.
@en
P2093
Gillenwater H
Socinski MA
Steagall A
P2860
P304
P356
10.3109/07357909909021419
P577
1999-01-01T00:00:00Z